Business Context and Reporting Period
Company: Biodesix, Inc. (BDSX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: Biodesix is a diagnostic solutions company focused on lung disease, offering blood-based diagnostic tests (Nodify, GeneStrat, VeriStrat) and biopharmaceutical services. The company operates clinical laboratories in Louisville, Colorado, and De Soto, Kansas.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $18,151 | $13,491 | $50,894 | $34,419 |
| Gross Profit | $13,972 | $10,262 | $39,663 | $24,783 |
| Gross Margin | 77.0% | 76.1% | 78.0% | 72.0% |
| Net Loss | $(10,258) | $(10,949) | $(34,680) | $(43,007) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.14) | $(0.28) | $(0.55) |
| Cash and Cash Equivalents (Sep 30, 2024) | $31,406 | |||
| Long-Term Debt (Principal) | $40,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% year-over-year (YoY) in Q3 2024 and 48% for the nine-month period. Diagnostic testing revenue grew 40% in Q3, driven by adoption of Nodify Lung Nodule Risk Assessment tests. Biopharmaceutical services revenue declined 17% in Q3 due to timing of sample receipts.
- Operating Expenses: Total operating expenses increased 29% in Q3 2024. Sales, marketing, general, and administrative expenses rose 29%, attributed to increased headcount, variable compensation, and depreciation from new Louisville facility leasehold improvements.
- Net Loss Improvement: Net loss narrowed by 6% in Q3 2024 compared to Q3 2023, despite higher operating expenses, due to significant revenue growth and the elimination of fair value losses on warrant liabilities recorded in the prior year.
- Debt and Contingent Consideration: The company prepaid the final $6.1 million exit fee and $8.4 million milestone payment related to the 2018 acquisition of Indi, eliminating the contingent consideration liability as of September 30, 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. This is due to a history of losses and dependence on executing the current operating plan to meet financial covenants under the Perceptive Term Loan Facility.
- Debt Covenants: The company is subject to Minimum Net Revenue covenants. On October 30, 2024 (subsequent to period end), the company entered a Fourth Amendment to reduce revenue thresholds through December 31, 2027. Failure to meet covenants could trigger an Event of Default.
- Liquidity: Cash balance decreased from $42.2 million in June 2024 to $31.4 million in September 2024. The company raised approximately $51.3 million in net proceeds in April 2024 via an underwritten offering and private placement.
- Regulatory Risk: The FDA is phasing out enforcement discretion for Laboratory Developed Tests (LDTs), which may require Biodesix to seek premarket authorization for its tests, potentially incurring significant costs and delays.
- Unusual Items: Hurricane Helene impacted test volumes in the southeast region at the end of Q3 2024. The company recorded a $0.2 million loss on extinguishment of liabilities in the nine months ended September 30, 2024, due to prepaying a contingent consideration milestone.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the amended Minimum Net Revenue thresholds under the Perceptive Term Loan Facility to avoid default.
- Cash Burn Rate: Monitor the rate of cash consumption against the $31.4 million cash balance to assess runway without additional capital raises.
- Revenue Concentration: Confirm continued reliance on Medicare (40% of revenue) and United Healthcare (7-10% of revenue) and potential impacts of reimbursement rate changes.
- FDA Regulatory Timeline: Track the company's progress in preparing for FDA regulation of LDTs, specifically the deadlines for high-risk tests (November 2027) and moderate/low-risk tests (May 2028).
- Capital Raise Plans: Review the status of the new $50.0 million ATM program expected to be filed in November 2024 and the utilization of the Lincoln Park Capital facility ($46.9 million remaining).